New Cancer Imaging Breakthrough?

For those battling aggressive lung and prostate cancers, every day can feel like an uphill battle.

But a new discovery at Memorial Sloan Kettering Cancer Center (MSK) is offering hope in the fight against these deadly diseases.

Scientists have developed a cutting-edge imaging technique that could change the game for detecting and treating some of the most challenging forms of cancer.

Here’s what you need to know about this exciting breakthrough…

The new imaging technology uses a radioactive particle that attaches to a specific molecule (called DLL3) found on certain cancer cells. This makes these cancer cells light up like a Christmas tree on PET scans, allowing doctors to spot them more easily.

Why is this such a big deal?

It targets the toughest cancers: This technique is especially good at finding small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC)—two aggressive types that are often hard to detect and treat.

This means it could guide better treatment. By identifying which patients have cancers with the DLL3 molecule, doctors can choose treatments that are more likely to work.

This type of imaging might catch cancer that other scans miss. It can spot tiny cancer spots in places like the brain that regular scans might not see. Additionally, current research shows it’s safe—In the first study with 18 patients, there were no safety concerns.

But here’s the most exciting part—this technology isn’t just about seeing cancer better; it could also lead to new ways to treat it.

Scientists are working on combining this imaging agent with cancer-fighting drugs. This would create a kind of “smart bomb” that could find and destroy cancer cells while leaving healthy cells alone.

Dr. Charles Rudin, one of the researchers behind this breakthrough, explains that about 70-80% of small cell lung cancers have the DLL3 molecule. This means many patients could potentially benefit from this new approach.

If you’re diagnosed with small cell lung cancer or neuroendocrine prostate cancer, ask your doctor about this new imaging technique. It might not be widely available yet, but it’s worth discussing.

And in the meantime, stay informed about clinical trials. As this technology develops, there may be opportunities to participate in studies testing new treatments based on this approach.

To brighter days and clearer scans ahead,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

P.S. Learn how machine learning is transforming diagnosis and treatments.

Source:

Tendler, S., et al. (2024). Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(24)00249-3